Top_20_Global_Therapy_Classes

2010 rank (US$) 2010 Sales (US$ MN) % Growth 2010 (LC$) 2009 Sales (US$ MN) % Growth 2009 (LC$) 2008 Sales (US$ MN) % Growth 2008 (LC$) 2007 Sales (US$ MN) % Growth 2007 (LC$) 2006 Sales (US$ MN) % Growth 2006 (LC$) Global Market 0 791,449$ 5.2 752,022$ 6.7 727,067$ 5.0 671,164$ 6.3 609,614$ 6.8 Oncologics 1 55,972$ 6.7 52,372$ 8.8 49,438$ 13.4 41,949$ 15.8 34,905$ 21.6 Lipid Regulators 2 36,400$ 2.0 35,281$ 4.9 34,445$ (1.2) 34,141$ (5.8) 35,358$ 7.9 Respiratory Agents 3 35,926$ 7.0 33,596$ 11.0 31,186$ 5.9 28,775$ 11.9 24,796$ 11.4 Antidiabetics 4 34,429$ 12.2 30,406$ 13.4 27,548$ 10.1 24,401$ 10.8 21,310$ 12.7 Anti-ulcerants 5 27,972$ (6.5) 29,610$ 0.6 30,032$ 0.0 29,174$ 2.6 27,619$ 3.0 Angiotensin II Antagonists 6 26,630$ 4.5 25,209$ 11.5 22,998$ 13.3 19,418$ 14.0 16,405$ 15.2 Antipsychotics 7 25,412$ 9.0 23,248$ 4.6 22,742$ 7.7 20,693$ 11.4 18,060$ 11.7 Autoimmune agents 8 20,710$ 14.7 17,961$ 18.0 15,612$ 19.3 12,815$ 17.4 10,629$ 21.6 Antidepressants 9 20,216$ 3.4 19,416$ (1.3) 20,194$ 1.1 19,581$ (6.2) 20,374$ 3.6 HIV Antivirals 10 15,432$ 13.2 13,758$ 14.9 12,280$ 12.7 10,699$ 12.8 9,175$ 10.9 Platelet Aggr. Inhibitors 11 15,244$ 1.8 14,604$ 9.0 13,647$ 10.4 11,952$ 8.7 10,624$ 8.1 Vitamins & minerals 12 12,971$ 6.1 11,951$ 9.5 11,374$ 8.7 10,109$ 6.9 9,026$ 4.2 Anti-epileptics 13 12,553$ (3.3) 12,995$ (19.8) 16,792$ 9.8 15,136$ 13.7 12,955$ 11.3 Narcotic analgesics 14 12,011$ 6.4 11,235$ 8.6 10,534$ 8.9 9,530$ 12.9 8,219$ (1.1) Cephalosporins & combs 15 11,466$ 6.1 10,586$ 6.9 10,188$ 3.4 9,489$ 2.8 8,849$ (4.8) Non-Narcotic Analgesics 16 10,986$ 0.0 10,917$ 7.5 10,896$ 4.2 10,179$ 8.0 8,862$ 3.2 Vaccines 17 10,972$ 2.8 10,690$ (1.6) 11,172$ (0.6) 10,911$ 43.6 7,311$ 19.7 Erythropoietins 18 10,596$ (2.3) 10,829$ (4.1) 11,486$ (13.0) 12,866$ (8.4) 13,791$ 12.0 Anti-Rheumatics, Non-Steroidal 19 10,152$ 3.6 9,668$ 3.0 9,897$ 3.6 9,318$ (2.8) 9,187$ (3.9) Multiple Sclerosis 20 9,844$ 13.8 8,712$ 16.8 7,716$ 19.9 6,245$ 8.8 5,533$ 8.4 Source: IMS Health Midas, December 2010 US$: Sales and Rank are in US$ with quarterly exchange rates LC$: Growth is in constant $ to normalize for exchange rate fluctuations Growth rates in US$ are not recommended due to extreme fluctuations in the value of the dollar Sales cover direct and indirect pharmaceutical channel wholesalers and manufacturers. The figures above include prescription and certain over the counter data and represent manufacturer prices. Therapy classes are defined as: Oncologics L1, L2 & Revlimid Platelet Aggr. Inhibitors B1C Lipid Regulators C10A & C10C&C11 Vitmains & Minterals A11 & A12 & A13 Respiratory Agents R3 Anti-epileptics N3A Antidiabetics A10C,A10H,A10J,A10K,A10L,A10M,A10N,A10S,A10X Narcotic analgesics N2A Anti-ulcerants A2B Cephalosporins & Combs J1D Angiotensin II Antagonists C9C & C9D & C9X Non-Narcotic Analgesics N2B Antipsychotics N5A Vaccines J7 Autoimmune agents M1C & Remicade & Cimzia (from L4A) Erythropoietins B3C Antidepressants N6A Anti-Rheumatics, Non-Steroidal M1A HIV Antivirals J5C Multiple Sclerosis L3B2&Copaxone&Tysabri Top 20 Global Therapeutic Classes, 2010, Total Audited Markets Top 20 Global Therapeutic Class